CVALF (CVALF) Stock Price & Analysis
CVALF (CVALF) rose 0.00% to USD 1.54 as of July 25, 2026 at 15:43 UTC, according to Nexqual real-time market data.
CVALF last closed at USD 1.54; the session ranged USD 1.54–1.54 on volume of 1,200 shares. Market capitalization is $42.53M, with a 52-week range of USD 1.16–2.14 (OQX). Source: Nexqual, July 25, 2026 at 15:43 UTC.
Key Statistics (as of July 25, 2026 at 15:43 UTC)
| Price | USD 1.54 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.54 |
| Open | USD 1.54 |
| Day Range | USD 1.54 – 1.54 |
| 52-Week Range | USD 1.16 – 2.14 |
| Volume | 1,200 shares |
| Market Cap | $42.53M |
| Exchange | OQX |
Technical Analysis (CVALF)
Nexqual's technical model rates CVALF "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 15:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.41 (neutral) |
| vs SMA50 | Above (USD 1.51) |
| MACD | 0 (positive) |
Analyst Ratings (CVALF)
Wall Street analysts rate CVALF "None", per Nexqual as of July 25, 2026 at 15:43 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CVALF)
| Next Earnings Date | 2026-08-20 |
|---|---|
| EPS Estimate | USD 0.02 |
| Revenue Estimate | $9.45M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.04 vs est 0.02 ▲ beat |
| 2025-12-31 | USD 0.01 vs est 0.04 ▼ miss |
| 2025-09-30 | USD 0.01 vs est -0.04 ▲ beat |
| 2025-06-30 | USD 0 vs est 0.04 ▼ miss |
Source: Nexqual, July 25, 2026 at 15:43 UTC.
Financials & Fundamentals (CVALF)
| Total Revenue | $32.68M |
|---|---|
| Revenue Growth (YoY) | +15.00% |
| Gross Margin | +54.19% |
| Operating Margin | +10.54% |
| Profit Margin | +5.02% |
| ROE | +5.55% |
| Debt / Equity | 6.33 |
| Current Ratio | 7.57 |
| Total Cash | $16.57M |
| Total Debt | $1.77M |
| Free Cash Flow | $3.37M |
Source: Nexqual, July 25, 2026 at 15:43 UTC.
Financial Health Score (CVALF)
Nexqual rates CVALF's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 15:43 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $17M cash vs $2M debt, net cash position |
| Cash Flow | Solid — FCF $3M, 10% margin |
| Efficiency | Mixed — ROE 6%, ROA 2.1% |
Ownership (CVALF)
| Insider Ownership | +47.16% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 27.62M |
| Float | 14.94M |
Source: Nexqual, July 25, 2026 at 15:43 UTC.
Leadership (CVALF)
CVALF is led by Brent Ashton, CEO & Director, per Nexqual as of July 25, 2026 at 15:43 UTC.
| CEO & Director | Brent Ashton |
|---|---|
| Co-Founder, Chief Scientific Officer & VP | Valerio DiTizio (age 57) |
| Chief Financial Officer | Katie Martinovich |
| COO & Director | Kimberley Crooks |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBXBF | MICROBIX BIOSYSTEMS | USD 0.22 | ▲ 0.92% |
| ACBM | ACRO BIOMEDICAL CO LTD | USD 0.03 | ▲ 0% |
| MCUJF | Medicure Inc. | USD 0.81 | ▼ 3.57% |
| BIOAF | BIOASIS TECHNOLOGIES INC | USD 0 | ▲ 0% |
| VIVXF | AVIVAGEN INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:43 UTC. This page is informational and not investment advice.